Your browser is no longer supported. Please, upgrade your browser.
GTHX G1 Therapeutics, Inc. daily Stock Chart
GTHX [NASD]
G1 Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.97 Insider Own17.81% Shs Outstand36.70M Perf Week7.77%
Market Cap905.76M Forward P/E- EPS next Y-3.68 Insider Trans0.00% Shs Float33.57M Perf Month9.79%
Income-111.10M PEG- EPS next Q-0.96 Inst Own97.30% Short Float14.29% Perf Quarter-31.97%
Sales- P/S- EPS this Y28.20% Inst Trans3.03% Short Ratio11.71 Perf Half Y24.96%
Book/sh7.62 P/B3.24 EPS next Y-11.90% ROA-32.40% Target Price66.50 Perf Year-20.92%
Cash/sh8.17 P/C3.02 EPS next 5Y- ROE-34.30% 52W Range13.87 - 41.80 Perf YTD28.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.96% Beta-
Dividend %- Quick Ratio14.30 Sales past 5Y- Gross Margin- 52W Low77.94% ATR1.39
Employees84 Current Ratio14.30 Sales Q/Q- Oper. Margin- RSI (14)64.37 Volatility5.83% 6.50%
OptionableYes Debt/Eq0.00 EPS Q/Q-46.40% Profit Margin- Rel Volume0.87 Prev Close24.10
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume409.62K Price24.68
Recom1.60 SMA2010.02% SMA5011.07% SMA2001.77% Volume355,076 Change2.41%
Aug-08-19Upgrade JP Morgan Neutral → Overweight
Feb-07-19Initiated B. Riley FBR Buy $55
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-20-18Initiated Raymond James Strong Buy
Nov-08-18Reiterated Needham Buy $76 → $74
Sep-10-18Resumed BTIG Research Buy $80
May-29-18Initiated H.C. Wainwright Buy $61
May-18-18Reiterated Needham Buy $42 → $60
Dec-11-19 06:00PM  G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS) GlobeNewswire
Nov-26-19 07:00AM  G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019 GlobeNewswire
Nov-21-19 09:44AM  Edited Transcript of GTHX.O earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 07:00AM  G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019 GlobeNewswire
Nov-08-19 08:49AM  We're Not Very Worried About G1 Therapeutics's (NASDAQ:GTHX) Cash Burn Rate Simply Wall St.
Nov-07-19 06:07AM  3 Biotech Stocks Needham Expects to Double in the Next 12 Months TipRanks
Nov-05-19 04:00PM  G1 Therapeutics Provides Third Quarter 2019 Corporate and Financial Update GlobeNewswire
Oct-29-19 07:00AM  G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019 GlobeNewswire
Oct-27-19 08:14PM  Here is What Hedge Funds Think About G1 Therapeutics, Inc. (GTHX) Insider Monkey
Sep-30-19 01:13PM  Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More Benzinga -32.94%
Sep-29-19 06:00AM  G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019 GlobeNewswire
Sep-28-19 04:15AM  G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival GlobeNewswire
Sep-10-19 06:01AM  G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress GlobeNewswire +10.99%
Sep-03-19 07:00AM  G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019 GlobeNewswire
Aug-28-19 07:27AM  Edited Transcript of GTHX.O earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 12:42AM  G1 Therapeutics, Inc. (GTHX) Q2 2019 Earnings Call Transcript Motley Fool +26.75%
Aug-07-19 04:01PM  G1 Therapeutics Provides Second Quarter 2019 Corporate and Financial Update GlobeNewswire
Aug-06-19 07:00AM  G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August GlobeNewswire
Jul-31-19 07:00AM  G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019 GlobeNewswire -7.25%
Jul-30-19 07:01AM  G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer GlobeNewswire
Jul-18-19 08:22AM  Hatteras Ventures-backed firm adds fresh round of capital American City Business Journals +7.02%
Jun-28-19 07:56PM  Did Hedge Funds Drop The Ball On G1 Therapeutics, Inc. (GTHX) ? Insider Monkey
Jun-23-19 09:00AM  These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now? Motley Fool
Jun-19-19 01:58PM  Harry Boxers three biotech stocks on the move include Nektar Therapeutics MarketWatch +7.22%
12:30PM  Why new cancer trial data is good news for a Triangle pharma American City Business Journals
09:48AM  Company News For Jun 19, 2019 Zacks
Jun-18-19 04:33PM  Why SunPower, Snap, and G1 Therapeutics Jumped Today Motley Fool +24.05%
03:14PM  What's Behind The Rally In Small-Cap Biotech G1 Therapeutics? Benzinga
06:00AM  G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer GlobeNewswire
Jun-14-19 07:01AM  G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019 Annual Meeting GlobeNewswire
Jun-13-19 07:01AM  G1 Therapeutics Announces Updates to Board of Directors GlobeNewswire
Jun-11-19 07:00AM  G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Conference GlobeNewswire
Jun-01-19 04:00PM  G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-19-19 09:29PM  Edited Transcript of GTHX.O earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-16-19 07:00AM  G1 Therapeutics to Present Additional Trilaciclib Phase 2 Small Cell Lung Cancer Data at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-13-19 01:12PM  G1 Therapeutics, Inc. (GTHX) Q1 2019 Earnings Call Transcript Motley Fool -8.15%
07:00AM  G1 Therapeutics to Present at UBS Global Healthcare Conference GlobeNewswire
May-12-19 09:04AM  Imagine Owning G1 Therapeutics (NASDAQ:GTHX) And Wondering If The 48% Share Price Slide Is Justified Simply Wall St.
May-09-19 04:01PM  G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update GlobeNewswire
May-05-19 08:15PM  Heres What Hedge Funds Think About G1 Therapeutics, Inc. (GTHX) Insider Monkey
May-02-19 07:00AM  G1 Therapeutics to Report First Quarter Financial Results on May 9, 2019 GlobeNewswire
May-01-19 02:15PM  G1 Therapeutics aims to expand as it approaches NDA filing American City Business Journals
Apr-30-19 03:21PM  Why G1 Therapeutics Is Soaring 16% Today Motley Fool +15.30%
02:28PM  G1 Therapeutics Hits Its Highest Level Of 2019: What You Need To Know Benzinga
08:06AM  The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering Benzinga
Apr-29-19 05:07PM  G1 Therapeutics stock rallies 25%; company to file application for new cancer drug MarketWatch
04:01PM  G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020 GlobeNewswire
Apr-02-19 07:00AM  G1 Therapeutics to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire +5.49%
Mar-05-19 06:08AM  Edited Transcript of GTHX.O earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-04-19 07:00AM  G1 Therapeutics to Present at Cowen and Company 39th Annual Healthcare Conference GlobeNewswire +9.77%
Feb-28-19 06:38PM  G1 Therapeutics, Inc. (GTHX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  G1 Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Feb-27-19 07:00AM  G1 Therapeutics to Host Investor Day 2019 on March 6, 2019 GlobeNewswire
Feb-21-19 07:00AM  G1 Therapeutics to Report Fourth Quarter and Full-Year 2018 Financial Results on February 28, 2019 GlobeNewswire
Feb-20-19 05:24PM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of G1 Therapeutics, Inc. Investors (GTHX) GlobeNewswire
Feb-11-19 06:41AM  Are Insiders Selling G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock? Simply Wall St.
Jan-23-19 08:11AM  5 Domestic Stocks to Gain From Thaw in Trade Talks Zacks
Jan-07-19 08:44AM  G1 THERAPEUTICS Enters Oversold Territory Zacks
Jan-03-19 02:48PM  From Iqvia to Red Hat: These execs raked in millions from stock sales in 2018 American City Business Journals -5.42%
Dec-27-18 09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
07:00AM  G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-18 11:00AM  Raymond James Keeps Bullish View on Biotech G1 After 43% Slide Bloomberg
Dec-20-18 05:27PM  Why G1 Therapeutics Got Hammered 42.6% Today Motley Fool -42.57%
10:28AM  G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results Benzinga
Dec-19-18 04:50PM  G1 Therapeutics stock dives on cancer-related infection drug study results MarketWatch
04:01PM  G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer GlobeNewswire
Dec-15-18 11:04AM  G1 Therapeutics, Inc. (GTHX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-06-18 07:25AM  New Research Coverage Highlights G1 THERAPEUTICS, Schlumberger, Adient, Camping World, Nutanix, and CNH Industrial N.V Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Dec-04-18 06:55AM  Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer GlobeNewswire
Nov-27-18 07:32AM  The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Benzinga -11.37%
Nov-26-18 04:01PM  G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer GlobeNewswire
Nov-21-18 09:32AM  Edited Transcript of GTHX.O earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 07:40PM  G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS) GlobeNewswire
Nov-07-18 04:01PM  G1 Therapeutics Reports Third Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Nov-06-18 07:00AM  G1 Therapeutics to Present at Investor Conferences in November 2018 GlobeNewswire
Oct-30-18 06:00AM  G1 Therapeutics to Provide Third Quarter 2018 Corporate and Financial Update on November 7, 2018 GlobeNewswire
Oct-21-18 08:45AM  G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer GlobeNewswire
Oct-09-18 07:00AM  G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress GlobeNewswire
Sep-26-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Sina, Paratek Pharmaceuticals, Honda Motor Co., Prospect Capital, G1 THERAPEUTICS, and Gaming and Leisure Properties New Research Emphasizes Economic Growth GlobeNewswire
Sep-21-18 04:05PM  G1 Therapeutics Announces Closing of Offering of Common Stock GlobeNewswire
Sep-19-18 09:41AM  G1 Therapeutics' stock drops on heavy volume after stock offering MarketWatch
08:47AM  The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering Benzinga
Sep-18-18 09:37PM  G1 Therapeutics Announces Pricing of Offering of Common Stock GlobeNewswire -5.21%
Sep-17-18 04:01PM  G1 Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
06:00AM  G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018 GlobeNewswire
Sep-13-18 07:00AM  G1 Therapeutics Announces Appointment of Garry Nicholson to Board of Directors GlobeNewswire
Sep-04-18 02:38PM  Inside The List: Highest-Paid Public Company CEOs American City Business Journals
Aug-28-18 06:00AM  G1 Therapeutics to Present at H.C. Wainwright Investment Conference on September 5, 2018 GlobeNewswire
Aug-09-18 05:10PM  G1 Therapeutics stock rises following earnings report American City Business Journals +8.97%
Aug-08-18 04:01PM  G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update GlobeNewswire
02:30PM  G1 Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 06:00AM  G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018 GlobeNewswire
Aug-01-18 06:00AM  G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018 GlobeNewswire +5.20%
Jul-09-18 05:25PM  The Triangle's top inside stock sales in the first half of 2018 American City Business Journals
07:00AM  G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel GlobeNewswire
Jun-25-18 08:08AM  G1 Therapeutics registers to sell $125 million worth of shares when needed in future American City Business Journals
Jun-08-18 07:00AM  G1 Therapeutics Announces Appointment of New Members to the Board of Directors GlobeNewswire
Jun-06-18 08:20AM  Analysis: Positioning to Benefit within China Biologic Products, Merus N.V, Adient, G1 Therapeutics, Westport Fuel, and AppFolio Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-04-18 05:34PM  Hatteras Venture Partners sells 20 percent of shares in G1 American City Business Journals -10.16%
Jun-02-18 09:00AM  G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.